On bias and transparency in the development of influential recommendations

CMAJ. Canadian Medical Association Journal

Volumn 174, Issue 3, 2006, Pages 335-336

  Laupacis, Andreas ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN GLARGINE; ISOPHANE INSULIN;

CLINICAL PRACTICE; CONFLICT OF INTEREST; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG MANUFACTURE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; HYPOGLYCEMIA; MEDICAL LITERATURE; MEDICAL SOCIETY; METHODOLOGY; NOTE; PRACTICE GUIDELINE; REIMBURSEMENT;

EID: 32544435635     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.051622     Document Type: Note

References (13)

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S1-152. Available: www.diabetes.ca/cpg2003 (accessed 2005 Dec 12).
2. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). CEDAC final recommendation on reconsideration and reasons for recommendation - insulin glargine. Available: www.ccohta.ca/CDR/cdr_pdf/cdr_submissions /Complete/cdr_complete_Lantus_2005Sept28.pdf (accessed 2005 Dec 11).
3. CCOHTA. Conflict of interest guidelines for the Common Drug Review. Available: www.ccohta.ca/CDR/cdr_pdf/CDR_Conflict_Interest_Guidelines.pdf (accessed 2005 Dec 21).
4. Easterbrook PJ, Berlin JA, Gopalan A, et al. Publication bias in clinical research. Lancet 1991;337:867-72.
5. Chan AW, Hrobjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published studies. JAMA 2004;291:2457-65.
6. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005;142:1090-9.
7. De Angelis CD, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Editors. CMAJ 2005;172 (13):1700-2. Available: www.cmaj.ca/cgi/content/full/172/ 13/1700 (accessed 2005 Dec 20).
8. Report of the Expert Advisory Panel on the Safety of Cox-2 Selective Non-steroidal Anti-inflammatory Drugs (NSAIDs). Available: www.hc-sc.gc.ca/dhp- mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/sap_report_gcs_rapport_cox2_e.pdf (accessed 2005 Dec 11).
9. Loew CJ. Conflicts of interest and independent data analysis in industry-funded studies [comment on JAMA 2005;294:110-1.]. JAMA 2005;294:2575, author reply 2576-7.
10. Canadian Coordinating Office for Health Technology Assessment. Common Drug Review - process. Available: www.ccohta.ca/entry_e.html (accessed 2005 Dec 11).
11. Canadian Diabetes Association. Canadian Diabetes Association concerned over recommendation to deny reimbursement for a new insulin diabetes treatment option [news release]. Available: www.diabetes.ca/Section_Main/NewsReleases.asp ?ID=124 (accessed 2005 Dec 9).
12. Howlett MC. Letter to the Honourable Ujjal Dosanjh, Minister of Health. Available: www.diabetes.ca/files/Federal-Glargiine-letter-final.pdf (accessed 2005 Dec 11).
13. EKOS Research Associates Inc. Common Drug Review (CDR) - evaluation. Available: www.ccohta.ca/CDR/cdr_evaluation_e.cfm (accessed 2005 Dec 11).